Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
With more Moon missions on the horizon, avoiding crowding and collisions will be a growing challenge - 2Step by step instructions to Involve Compact disc Rates for Magnanimous Giving
- 3Cruising Solo All over the Planet: An Excursion of Self-Disclosure
- 4The Best Computer games for Multiplayer Fun
- 5Pick Your #1 game to observe
- Esteem Stuffed Gaming Workstations to Consider
- Jamaica reports deadly leptospirosis outbreak after Hurricane Melissa
- Who is behind Al-Majd, the Israeli-linked evacuation group sending Gazans to South Africa?
- Gaza Strip sees flooding after heavy rainfall
- Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
- Insurance warning signs in doctors’ offices might discourage patients from speaking openly about their health
- Newly discovered link between traumatic brain injury in children and epigenetic changes could help personalize treatment for recovering kids
- Polar bears are rewiring their own genetics to survive a warming climate
- The most effective method to Explore Moral Situations in Brain research with Your Certification
